Michael Makris/LinkedIn
Mar 2, 2026, 13:42
Michael Makris: How Early Can Hemlibra Be Started?
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Eman Hassan et al, published in RPTH Journal:
”How early can you start Hemlibra (emicizumab)?
A paper in the RPTH Journal describes its effective use when started at 26 hours of age, in a baby with hemophilia born 10 weeks premature (at 30 weeks of gestation).”
Title: Emicizumab Prophylaxis in a Preterm Infant with Severe Haemophilia A: A Case Report on the Feasibility of Early Use
Authors: Eman Hassan, Charles Percy, Amna Ahmed, Gillian Lowe, Will Lester, Neil V. Morgan, Jayashree Motwani
Read the Full Article on RPTH Journal․
Other articles featuring Michael Makris on Hemostasis Today.
-
Jul 18, 2026, 15:49Heghine Khachatryan: ISTH 2026 – Final Day Highlights
-
Jul 18, 2026, 15:40Marc Carrier: New ISTH 2026 Data May Simplify DVT Evaluation During Pregnancy
-
Jul 18, 2026, 15:38Hermine Sayiyan: Dreams Do Come True – Often When We Least Expect Them
-
Jul 18, 2026, 15:31Alyaa Al-Mughairy: Presenting Real-World Emicizumab Data at the ISTH 2026 Middle East Summit
-
Jul 18, 2026, 15:25Rim Diab: Presenting Protein S Research as a Rebalancing Strategy at ISTH 2026
-
Jul 18, 2026, 15:22Owen McCarty: Honored to Speak at the 1st Mediterranean Platelet Symposium
-
Jul 18, 2026, 15:18Strengthening Regional Learning for Hemophilia and Sickle Cell Disease Care – Novo Nordisk
-
Jul 18, 2026, 14:54Fabien Mselati: Reflecting on 25 Years of Hemophilia Progress
-
Jul 18, 2026, 14:50Nikola Pantic: Grateful for the People Who Made ISTH 2026 Special